ChromaDex Corp. (NASDAQ:CDXC), shares were static Wednesday, as the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research announced its inaugural initiative to support the U.S. Military.
As the most efficient, studied, and high-quality NAD+ boosting supplement on the market, ChromaDex’s patented nicotinamide riboside (NR) supplement, Tru Niagen®, is now being utilized by US Military Special Operations Forces, marking a significant milestone in the product's journey toward promoting cellular health and resilience. In a gesture of gratitude and further support US troops, ChromaDex has launched an exclusive program that offers Tru Niagen products to active and veteran Military Service Members. This initiative reflects ChromaDex’s commitment to the health and well-being of those who serve the Nation.
NAD+ is an essential coenzyme vital for cellular health and NR is the most efficient way to elevate NAD+ levels due to its ability to cross directly through the cell membrane. Clinically proven to safely and effectively increase NAD+, Tru Niagen supports cellular energy, combats physiological stress, and aids in cellular repair and recovery – all of which are vital for the physically demanding environments encountered in military operations.
“Tru Niagen,” according to this morning’s news release, “embodies the highest scientific rigor and quality standards and is backed by two Nobel Prize winners, 30+ human clinical studies, 300 published scientific studies, and accepted by the world’s most rigorous regulatory bodies.”
CDXC shares were having trouble getting off their initial perch of $1.40.
